Assessment of efficacy of secondary prophylactic complex of bronchial obstruction syndrome in young children with respiratory disorders in neonatal period: analysis of symptoms and serological markers

IF 0.9 Q4 IMMUNOLOGY
Matsyura Oksana, Besh Lesya, Zubchenko Svitlana, Gutor Taras, Lukyanenko Natalia, Slivinska-Kurchak Khrystyna, Borysiuk Olena
{"title":"Assessment of efficacy of secondary prophylactic complex of bronchial obstruction syndrome in young children with respiratory disorders in neonatal period: analysis of symptoms and serological markers","authors":"Matsyura Oksana, Besh Lesya, Zubchenko Svitlana, Gutor Taras, Lukyanenko Natalia, Slivinska-Kurchak Khrystyna, Borysiuk Olena","doi":"10.3934/allergy.2022005","DOIUrl":null,"url":null,"abstract":"Diseases of respiratory tract in young children are often accompanied by the development of bronchial obstruction syndrome. Recurrent episodes of bronchial obstruction are a common problem in young children with respiratory disorders in neonatal period. The aim of our work was to test secondary prophylactic measures concerning development and progression of recurrent bronchial obstructive syndrome in young children, who had suffered respiratory disorders in neonatal period. Prophylactic complex included basic therapy (inhalation of glucocorticosteroids—fluticasone propionate or budesonide), administration of immunomodulating drug Ribomunyl and conducting of prophylactic vaccination in specialized inpatient department after prior preparation whith antihistamines. Objectives The feature of disease course was assessed based on the need of using drugs with symptomatic action, frequency of exacerbations, their mean duration and severity in 60 children, who had breathing disorders in neonatal period. Children were randomly divided into two groups. The study of efficacy of secondary prophylactic measures was conducted in 30 children (basic group) and in other 30 patients secondary prophylactic complex was not used (control group). Methods Algorithm of secondary prophylactic complex included basic therapy involving inhalation glucocorticosteroids, administration of immunomodulatory drug Ribomunyl as recommended and conduction of planned prophylactic inoculations with the use of antihistamines. Conclusions In children, who were administered secondary prophylactic complex was a positive dynamics in clinical picture and laboratory data. Results Administration of secondary prophylactic complex enabled, to a certain extent, to prevent progression of bronchial obstructive syndrome and achieve a reliable increase in γ-INF, IgA, IgM, IgG levels and decrease in IL-4 (р < 0.01).","PeriodicalId":40916,"journal":{"name":"AIMS Allergy and Immunology","volume":null,"pages":null},"PeriodicalIF":0.9000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"AIMS Allergy and Immunology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3934/allergy.2022005","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 2

Abstract

Diseases of respiratory tract in young children are often accompanied by the development of bronchial obstruction syndrome. Recurrent episodes of bronchial obstruction are a common problem in young children with respiratory disorders in neonatal period. The aim of our work was to test secondary prophylactic measures concerning development and progression of recurrent bronchial obstructive syndrome in young children, who had suffered respiratory disorders in neonatal period. Prophylactic complex included basic therapy (inhalation of glucocorticosteroids—fluticasone propionate or budesonide), administration of immunomodulating drug Ribomunyl and conducting of prophylactic vaccination in specialized inpatient department after prior preparation whith antihistamines. Objectives The feature of disease course was assessed based on the need of using drugs with symptomatic action, frequency of exacerbations, their mean duration and severity in 60 children, who had breathing disorders in neonatal period. Children were randomly divided into two groups. The study of efficacy of secondary prophylactic measures was conducted in 30 children (basic group) and in other 30 patients secondary prophylactic complex was not used (control group). Methods Algorithm of secondary prophylactic complex included basic therapy involving inhalation glucocorticosteroids, administration of immunomodulatory drug Ribomunyl as recommended and conduction of planned prophylactic inoculations with the use of antihistamines. Conclusions In children, who were administered secondary prophylactic complex was a positive dynamics in clinical picture and laboratory data. Results Administration of secondary prophylactic complex enabled, to a certain extent, to prevent progression of bronchial obstructive syndrome and achieve a reliable increase in γ-INF, IgA, IgM, IgG levels and decrease in IL-4 (р < 0.01).
新生儿期呼吸系统疾病患儿支气管阻塞综合征二级预防复合物的疗效评价:症状和血清学指标分析
幼儿呼吸道疾病常伴有支气管阻塞综合征的发展。支气管阻塞反复发作是新生儿期呼吸系统疾病患儿的常见问题。我们工作的目的是测试二级预防措施有关复发性支气管阻塞性综合征的发展和进展的幼儿,谁在新生儿期遭受呼吸系统疾病。预防性综合治疗包括基础治疗(吸入糖皮质激素-丙酸氟替卡松或布地奈德),给予免疫调节药物利博门尼,并在事先准备抗组胺药后在专科住院部进行预防性接种。目的对60例新生儿期呼吸障碍患儿的病程特点进行评价,包括对有症状作用药物的使用需求、加重次数、平均持续时间和严重程度。孩子们被随机分成两组。对30例患儿(基础组)进行二级预防措施的疗效研究,其余30例患儿未使用二级预防复合物(对照组)。方法二级预防方案包括吸入糖皮质激素的基础治疗、推荐使用免疫调节药物利博门尼和使用抗组胺药进行有计划的预防接种。结论儿童口服二级预防复合物在临床表现和实验室数据上均为积极动态。结果给予二级预防复合物能在一定程度上预防支气管阻塞性综合征的进展,γ-INF、IgA、IgM、IgG水平明显升高,IL-4水平明显降低(p < 0.01)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
10
审稿时长
4 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信